JapanStake
Services · Fiscal year end Mar 31

TRANS GENIC GROUP INC.

2342

株式会社トランスジェニックグループ

FIGI BBG000BLMTL92342.T2342 JPCorp. no. 9330001006698

Latest half-year results

First half · fiscal year to 2026-03 · filed 2025-11-13

For the first half of the fiscal year to 2026-03: Revenue ¥6.2 billion (-1.4% YoY), Ordinary income ¥0.1 billion, Net income ¥0 billion.

This periodYear on year
Revenue¥6.2bn-1.4%
Ordinary profit¥83m—
Net profit to owners¥30m—

From the securities report on EDINET, which states no forecast. History via /v1/companies/2342/earnings-releases.

Financials

Japan GAAP · consolidated · fiscal year to 2026-03-31
Revenue
¥13.2bn
Net income
−¥77m
ROE
—
Equity ratio
49.1%
Dividend / share
—
Employees
227
Revenue · ¥bn
FY2022: ¥12.6bn 12.6 FY2022FY2023: ¥11.4bn 11.4 FY2023FY2024: ¥13.1bn 13.1 FY2024FY2025: ¥13.0bn 13 FY2025FY2026: ¥13.2bn 13.2 FY2026
Net income · ¥bn
FY2022: ¥1.9bn 1.88 FY2022FY2023: −¥0.4bn -0.41 FY2023FY2024: ¥0.0bn 0 FY2024FY2025: −¥1.1bn -1.09 FY2025FY2026: −¥0.1bn -0.08 FY2026
Fiscal yearRevenueNet incomeTotal assetsNet assetsROEEPSOperating CF
2026-03-31¥13.2bn−¥0.1bn¥9.7bn¥4.8bn—¥-4.64¥0.0bn
2025-03-31¥13.0bn−¥1.1bn¥9.6bn¥4.9bn—¥-65.51¥0.1bn
2024-03-31¥13.1bn¥0.0bn¥9.8bn¥6.0bn0.1%¥0.24−¥0.4bn
2023-03-31¥11.4bn−¥0.4bn¥10.7bn¥6.1bn—¥-24.32−¥1.4bn
2022-03-31¥12.6bn¥1.9bn¥10.4bn¥6.6bn32.8%¥109.52¥1.8bn

Indicators

Computed by us from filings · fiscal year to 2026-03-31
MetricValuePercentile among listed companies
ROE, %——
Ordinary margin0.00912
Equity ratio, %49.140.1
Revenue growth0.01330.8
Net income growth0.929183.9
Operating cash flow / assets0.002717
Policy-uncertainty measure0.74 Share of the report's text discussing policy-related uncertainty, by policy area. Proprietary text method.
Politics & geopolitics 1
Ownership activity 0 filer(s) stated they may make proposals in 365 days; 0 new 5% holder(s) in 180 days; net stake change 0.00pt in 90 days; 0.0% held by other listed companies.

Results wording balance: -0.08. Proprietary text method; it describes the wording only and does not interpret context.

Interest example: if all ¥2.1bn of reported debt repriced by 50 basis points, a year's interest would rise by ¥10m, 40.3% of operating cash flow. Our arithmetic only, not a forecast: fixed-rate debt and hedges are ignored.

Via /v1/companies/2342/indicators. Descriptive figures, not a rating and not investment advice.

From other filings

As the company states them
Internal control, 2026-06-17: see filing 上記の評価の結果、当事業年度末日時点において、当社グループの財務報告に係る内部統制は有効であると判断いたしました。 Filing

Segments, votes and tender offers

Stated in EDINET filings
Segments: Drug Discovery Support Business, Investments and Consulting Business. /v1/companies/2342/segments

Cross-shareholdings

From the annual report's status of shareholdings
Listed strategic holdings
1 issues
Book value
¥215m
Sold in the year
¥153m 1 issues
Bought in the year
— — issues
Mutual, both reports
0
Held by listed cos.
0
HoldsBook valueShares vs. prior yearMutual
Immuno-Biological Laboratories Co., Ltd. 4570¥215m-22.0%no

Purposes, all holdings and mutual flags via /v1/companies/2342/cross-holdings. Share changes include stock splits.

Major shareholders

As of fiscal year end 2026-03-31
ShareholderSharesRatio
individual holder309,9001.86%
individual holder237,7001.42%
モルガン・スタンレーMUFG証券株式会社232,6001.39%
BNYM SA/NV FOR BNYM FOR BNY GCM CLIENT ACCOUNTS M LSCB RD202,1581.21%
individual holder191,5001.14%
individual holder173,0001.03%
individual holder170,0001.02%
野村證券株式会社162,9930.97%
株式会社ムトウ160,2000.96%
individual holder150,0000.90%

Get this as JSON

GET /v1/companies/2342
GET /v1/companies/2342/financials
GET /v1/companies/2342/details
GET /v1/companies/2342/segments
GET /v1/companies/2342/voting
GET /v1/companies/2342/tender-offers
GET /v1/companies/2342/indicators
GET /v1/companies/2342/earnings-releases
GET /v1/events?ticker=2342
GET /v1/companies/2342/trades         
GET /v1/companies/2342/cross-holdings 
GET /v1/companies/2342/brief

Plans from $9 a month · Documentation